ALK Positive Lung Cancer Definition and Treatment

EML4-ALK in Lung Cancer and the Role of Crizotinib

strand of DNA with a base pair highlighted
What is ALK positive lung cancer and how is it treated?. istockphoto.com

If your doctor has told you that you have an ALK rearrangement or ALK-positive lung cancer, you may feel like you are in a country that speaks a foreign language without an interpreter. What exactly is ALK, how common is the ALK mutation, and how are people with ALK-positive lung cancer treated?

Definition of an ALK Mutation

An ALK mutation is an abnormality in a gene that can occur in cancer cells such as lung cancer cells.

As a quick review, genes are the parts of chromosomes in our DNA that code for things such as our eye color and hair color. They are also the blueprint that codes for proteins that run the processes that keep our bodies running smoothly – or cause cells to divide and grow.

Cancer cells are cells that have undergone several gene mutations – changes in genes, in the process of becoming cancer cells. Like humans, every cancer is different, and carries different mutations. These mutated genes in turn code for proteins that are abnormal and perform abnormal functions – such as driving the growth of a cancer.

Discovered in 2007, an ALK mutation is a mutation in a gene called ALK (anaplastic lymphoma kinase.) To be more accurate, this mutation is actually a gene rearrangement – a fusion of 2 genes known as ALK and EML4 (echinoderm microtubule-associated protein like 4.) This abnormal gene (a fusion gene) in turn codes for an abnormal protein called tyrosine kinase (there are many types of tyrosine kinases.) Tyrosine kinases are enzymes (proteins) that act as chemical messengers, sending signals to the cells growth center which tell that cell to divide and multiply.

Simplistically, tyrosine kinase “drives” or dictates the growth of a cancer (mutations such as the EML4-ALK fusion gene are known as “driver mutations.”)

The exciting part of this discovery is that now some cancers can be treated with tyrosine kinase inhibitors, drugs that block tyrosine kinase (in this case the fusion protein EML4-ALK) and inhibit the growth of the cancer by blocking the signals that tell the cell to divide.

By essentially controlling the cancer “on-off” switch, these medications have improved the lives of some people living with cancer who have ALK mutations.

Some people are familiar with another mutation found in some people with non-small cell lung cancer, called an EGFR mutation. This mutation also results in the formation of abnormal tyrosine kinase proteins, and the EGFR tyrosine kinase inhibitor Tarceva (erlotinib) has extended the life of many people with lung cancer who have a tumor positive for this mutation.

The following articles talk further about the role of mutations in cancer cells:

What is ALK-Positive Lung Cancer?

ALK positive lung cancer refers to people who have a lung cancer that tests positive for an ALK mutation (the EML4-ALK fusion gene.) This mutation is present in 3 to 5 percent of people with non-small cell lung cancer. That may sound like a small number at first glance, but considering the large number of people diagnosed with lung cancer each year in the U.S. (over 200,000 in 2009, the last year for which statistics are available,) that number is actually quite large.

This fusion gene is also found in some people with neuroblastoma and anaplastic large cell lymphoma.

A confusing and important point to note is that this isn’t a hereditary mutation like the BRCA1 and BRCA2 mutations in some people with breast cancer that we are hearing about. People who have a lung cancer positive for the EML4-ALK fusion gene weren’t born with cells that had this mutation and didn’t inherit a tendency to have this mutation from their parents. Instead, this is an acquired mutation that develops in some cancer cells as a part of cancer development.

Diagnosis

An ALK mutation is diagnosed by molecular profiling of a sample of the tumor. It’s important in doing this testing that an adequate supply of tissue from either a lung biopsy or lung cancer surgery is obtained. Researchers are also looking at ways to determine if an ALK mutation is present before genetic testing is done, or could substitute for genetic testing. A few things that suggest an ALK mutation may be present include:

  • Bloodwork – A test called CEA (carcinoembryonic antigen) tends to be negative in people with ALK mutations.
  • Radiology – In one study, tumors positive for ALK appeared solid and did not have something called ground glass appearance. In contrast, 50 percent of those without the mutation had radiology studies with a ground glass appearance.

At this time, however, molecular profiling (genetic testing) remains the best test and is the standard of care.

Who is Likely to Have an ALK Mutation?

The types of mutations present in lung cancers vary depending upon the type of lung cancer. EML4-ALK fusion genes are by far most common in people with the type of non-small cell lung cancer called lung adenocarcinoma. That said, in rare cases ALK has been found in people with squamous cell carcinoma of the lungs (another type of non-small cell lung cancer) and small cell lung cancer.

There are also certain people who are more likely to have the ALK fusion gene. This includes younger patients, people who have never smoked (or smoked very little), women, and those with East Asian ethnicity. In a recent study, it was found that patients younger than 40 years of age tested positive for the EML4-ALK fusion gene almost 50 percent of the time (in contrast to 3 to 5 percent of people of all ages with lung cancer.)

Who Should be Tested for an ALK Mutation?

Several organizations have worked together to develop guidelines on who should be tested for an ALK mutation. The consensus was that all patients with advanced-stage adenocarcinoma should be tested for both ALK and EGFR mutations, regardless of gender, smoking history, other risk factors, and race.

One limitation is that some tumors have areas that appear to be different types of lung cancer. For example, the tissue in one part of a biopsy may look like adenocarcinoma and the tissue in another part of the biopsy sample may look like small cell lung cancer.

There are some exceptions physicians may make to these guidelines. For example, testing may be recommended for someone who has never smoked, even though their type of lung cancer does not appear to be adenocarcinoma. These guidelines will likely change as more is learned about these mutations, and other mutations are discovered and subsequent treatments developed.

How is ALK Positive Lung Cancer Treated?

Even though ALK mutations in lung cancer were just discovered in 2007, a treatment for people who have this mutation (and also have metastatic lung cancer) has already been approved by the FDA. This FDA approval – just 4 years after the discovery of the rearrangement – is exciting amidst a background of lung cancer treatments that haven’t increased survival significantly in the last several decades.

How does it work? The medication - Xalkori (crizotinib) is an inhibitor of tyrosine kinase. In this case, Xalkori binds to the tyrosine kinase receptor on the surface of lung cancer cells and inhibits the abnormal ALK protein. An easier way to understand this is to think of the tyrosine kinase receptor as a lock, and the tyrosine kinase protein (made by the abnormal gene) as a key. People with an ALK mutation have an abnormal key. When the key is “inserted,” signals are sent to the growth center to have cells divide without stopping. Medications such as Xalkori work by blocking the keyhole – sort of like if you filled the keyhole on your front door with concrete. Since the key (the abnormal protein) is unable to enter the lock (bind with the receptor,) the signal for the cell to divide and grow never reaches the control station and cell division (growth of the tumor) is halted.

How well does it work? Studies have found that treatment with Xalkori results in a median progression-free survival of 7 to 10 months. There is roughly a 50 to 60% response rate to the drug. This may not seem dramatic, especially when compared to treatments for some other cancers, but it's noteworthy that the people in these studies had already received and failed previous chemotherapy and the expected response rate to further traditional chemotherapy would only be around 10% with an average progression-free survival of around 3 months.

Even though the response rate with Xalkori is better than with standard chemotherapy, studies haven’t found that Xalkori increases overall survival. Yet while survival is important, quality of life is also important. Delaying the progression of cancer likely reduces symptoms related to the cancer, and in fact, patients treated with Xalkori had fewer symptoms related to their lung cancer (less shortness of breath, chest pain, and fatigue.) It’s also uncertain whether this study accurately assessed survival rate since people in this study were allowed to “cross-over” and use the other treatment if their symptoms progressed. More people stopped chemotherapy and switched to crizotinib than the other way around.

Since Xalkori was approved, 2 additional       zykadia  alecensa (

It’s important to keep in mind that tyrosine kinase inhibitors are not a cure for lung cancer, but rather something that allows a tumor to be “kept in check” much as a medication for diabetes may control the disease but does not cure it. It is hoped that in the future, lung cancer, at least certain types with certain mutations, may be treated like other chronic diseases such as diabetes.

Resistance

Unfortunately, even though over half of people respond well to treatment, resistance almost always develops over time and the drug loses effectiveness. For people who develop resistance, there are still options available. Alectinib was granted breakthrough designation in 2013 for people with ALK-positive lung cancer resistant to crizotinib.  In March of 2014 another medication - Zykadia (ceritinib) - was granted breakthrough treatment by the FDA.  Initial response rates to Zykadia were similar to those with Xalkori.  In addition - many people who had developed resistance to Xalkori responded to Zykada. New medications are being studied in clinical trials for people who develop resistance, and some researchers hope that in the future patients may be treated in a sequential fashion with these drugs as resistance develops.

 In addition, tumors often change (develop new mutations) over time. Sometimes a medication that targets another treatable mutation (such as EGFR) may work even though a tumor was not initially positive for an EGFR mutation.  It is hoped that in the near future we will be able to treat lung cancer -- at least this subtype - in much the same way we treat other chronic diseases.

Side Effects of Treatment

As with so many treatments for cancer, medications such as Xalkori have side effects. Thankfully many of these are much milder than what people experience during traditional chemotherapy. The most common symptoms people experience on Xalkori include visual problems, diarrhea, nausea, shortness of breath, and abnormal liver function tests. A rare but severe side effect that has been noted is the development of interstitial lung disease which can be fatal.

The Future

The ALK fusion gene is but one of many mutations present in lung cancer cells. It is hoped that as these are better understood, new targeted treatments will become available that will not only counteract resistance but target other abnormalities (driver mutations) in cancer cells. With regard to crizotinib, it’s thought that the drug may also help some people who don’t have the ALK fusion gene, but have other abnormal tyrosine kinase genes (such as a ROS1 rearrangement.)

Final Comments

In order for medications to be used that target mutations such as ALK, people with lung cancer must be tested for the mutation. While guidelines recommend testing for everyone with advanced adenocarcinoma and the use of this technology is increasing, there are still many people who are never offered the test.

There are a few reasons for this. One is that this is a very rapidly changing area of medicine, and no doctor can be on top of every new finding. Ask questions. Do a little research (or have a friend or loved one research your tumor.) Consider getting a second opinion at a cancer center that sees a large volume of lung cancer patients.

Another concern is the cost. The newer medications that target abnormalities in cancer cells often come with a steep price tag. But there are options available. For those who don’t have insurance, there are government as well as private programs that can help. For those with insurance, copay assistance programs may help defray costs. In some cases, the manufacturer of the drug may be able to supply medications at a reduced cost. And importantly, as a participant in a clinical trial, medications as well as office visits are often provided free of cost.

As a final note, no matter how much you learn from your medical team, there is nothing like hearing from people who have actually been there and received the treatments you are likely to receive. Check out support groups for people with lung cancer and ask if anyone else has an ALK mutation. Some organizations such as LUNGevity have a matching service (the LUNGevity LifeLine) in which they can even match you with someone with lung cancer who has a similar type and stage of tumor.

Sources:

American Association for Cancer Research. New Findings Open Doors For Rational Lung Cancer Treatment Strategies. 09/18/14..http://blog.aacr.org/findings-open-doors-rational-lung-cancer-treatment-strategies/

Bang, Y. Treatment of ALK-Positive Non-Small Cell Lung Cancer. Archives of Pathology and Laboratory Medicine. 2012. 136(10):1201-4.

Calio, A. et al. ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung. Journal of Thoracic Oncology. 2014. 9(5):729-32.

CDC. Lung Cancer Statistics. Updated 12/20/12. http://www.cdc.gov/cancer/lung/statistics/

Doebele, R. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clinical Cancer Research. 2012. 18(5):1472-82.

Dacic, S. Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. Journal of Clinical Pathology. 2013 Jun 25. (Epub ahead of print).

Forde, P., and C. Rudin. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opinion in Pharmacotherapy. 2012. 13(8):1195-201.

Fukui, T. et al. Lung Cancer. 77(2):319-325.

Garber, K. ALK, Lung Cancer, and Personalized Therapy: Portent of the Future?. Journal of the National Cancer Institute. 2010. 102(10):672-675.

Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Science Translational Medicine. 2012. 4(12):120ra17.

Katayama, R. et al. Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib. Clinical Cancer Research. Pubished OnlineFirst September 16, 2014.

Kim, S. et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. Journal of Thoracic Oncology. 2013. 8(4):415-22.

Lindeman, N. et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association of Molecular Pathology. Journal of Molecular Diagnostics. 2013. 15(4):415-53.

Nagashima, O. et al. High prevalence of gene abnormalities in young patients with lung cancer. Journal of Thoracic Disease. 2013. 5(1):27-30.

Ou, S. et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012. 17(11):1351-75.

Pluzanski, A., Piorek, A., and M. Krzakowski. Crizitinib in the treatment of non-small-cell lung carcinoma. Contemporary Oncology (Pozn). 2012. 16(6):480-484.

Ren, S. et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochemistry and Biophysiology. 2012. 64(2):155-60.

Shaw, A. et al. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. The New England Journal of Medicine. 2013. 368:2385-2394.

Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007. 448(7153):561-6.

Sundem G. University of Colorado Cancer Center. ALK-positive lung cancer develops crizotinib resistance – now what? 06/04/12. http://www.coloradocancerblogs.org/alk-positive-lung-cancer-develops-crizotinib-resistance-now-what/

Toyokawa, G. et al. Lung Cancer. Published online 19 June 2013.

Continue Reading